Stellar Biotechnologies Expands Operations Team

LOS ANGELES, June 7, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's, diabetes and lupus, among other diseases, today announced that the company has expanded its operations team, including key additions in manufacturing and aquaculture. The new managers and scientists are part of the company's plans to optimize its manufacturing process and increase throughput capacity.

"These scientists and industry experts bring valuable experience in scaling up production, process validation and regulatory compliance, and we are confident that they will contribute greatly to our growth initiatives," said Gregory T. Baxter, PhD, Stellar Executive Vice President of Corporate Development. He noted that Stellar's supply strategy includes expanding the footprint of its aquaculture technology platform and increasing the capacity of its manufacturing systems.

To support protein processing and manufacturing, Stellar hired Liliana Marghitoiu to lead its quality control department. She brings more than 12 years of experience in expanding quality, regulatory and compliance programs for pharmaceutical manufacturing operating under GMP (Good Manufacturing Practice) standards. Marghitoiu holds Master's of Science degrees in regulatory affairs and biotechnology from the University of Southern California and California State University Channel Islands, respectively.

The company also expanded its senior aquaculture team with the addition of Kalam Azad, PhD. Dr. Azad has more than 25 years of experience developing novel aquaculture production systems, most recently at the Centre for Aquaculture and Environmental Research. He has worked extensively in Southeast Asia and Bangladesh, and spent 12 years in North America developing new hatchery and production technologies for various shellfish, including giant keyhole limpet. Azad has published his research in multiple scientific journals, including Aquaculture, Environmental Management and World Aquaculture. He received his doctorate degree from the University of British Columbia.

In Mexico, Stellar appointed Luis Gonzalez Agraz as the General Manager of the company's local subsidiary. He will oversee Stellar's development projects in Mexico. Agraz most recently served for six years as the Director of Aquaculture for the Mexican state of Baja California. In addition to his high profile government role in the industry, since 2001, Agraz has provided consultancy services to various aquaculture start-ups and projects in Mexico. He holds a Master's of Science degree in aquaculture and marine biotechnology from the Center for Scientific Research and Higher Education at Ensenada.

About Stellar Biotechnologies
Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies.

Follow Stellar: LinkedIn | Twitter | Facebook | Google+

Stellar Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; changes in trade policy and international law; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.

SOURCE Stellar Biotechnologies, Inc.

Related Links

http://www.stellarbiotechnologies.com